Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 2.73B |
| Revenue (ttm) | 460.48M |
| Net Income (ttm) | 142.80M |
| Shares Out | 119.27M |
| EPS (ttm) | 1.18 |
| PE Ratio | 19.40 |
| Forward PE | 16.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 722,720 |
| Open | 22.87 |
| Previous Close | 22.92 |
| Day's Range | 22.65 - 23.13 |
| 52-Week Range | 13.12 - 24.27 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 32.86 (+43.68%) |
| Earnings Date | Feb 26, 2025 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type... [Read more]
Financial Performance
In 2023, Catalyst Pharmaceuticals's revenue was $398.20 million, an increase of 85.90% compared to the previous year's $214.20 million. Earnings were $71.41 million, a decrease of -14.05%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CPRX stock is "Strong Buy." The 12-month stock price forecast is $32.86, which is an increase of 43.68% from the latest price.
News
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most S...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epil...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in Febr...
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Richard Daly - President and Chief Executive Officer Michael Kalb - Chie...
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
Reports Q3 2024 Total Revenues of $ 128.7 Million, Representing a 25.3 % YoY Increase
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de...
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
Top 3 Health Care Stocks That May Crash In August
As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript
Call End: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - Preside...
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch
Top 3 Health Care Stocks You May Want To Dump This Quarter
As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET
These small-cap stocks score highest when screened for quality
After years of dominance by the largest tech companies in the U.S. stock market, interest is spreading to overlooked companies that might be a better value for investors looking to diversify, lower th...
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, deve...
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, deve...
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Exe...